Company GTx, Inc. Nasdaq

Equities

US40052B2079

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâs product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

USD in Million	2022	Weight	2023	Weight	Delta
Novel Oncology Therapies 100.0 %	1	100.0 %	1	100.0 %	-47.32%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	1	100.0 %	1	100.0 %	-47.32%

Managers	Title	Age	Since
James Breitmeyer FOU	Founder	70	96-12-31
Richard Vincent DFI	Director of Finance/CFO	61	17-03-31
Salim Yazji CTO	Chief Tech/Sci/R&D Officer	55	21-05-16
Rajesh Krishnan CTO	Chief Tech/Sci/R&D Officer	51	19-08-27
Pablo Urbaneja PRN	Corporate Officer/Principal	-	21-06-30
Anita Wiseth HRO	Human Resources Officer	-	21-02-28
Chase Leavitt LAW	General Counsel	42	21-04-11

Members of the board	Title	Age	Since
David Hale FOU	Founder	75	97-08-31
Dan Kisner BRD	Director/Board Member	77	19-06-06
Rosemary Mazanet BRD	Director/Board Member	68	21-01-26
James Breitmeyer FOU	Founder	70	96-12-31
William LaRue BRD	Director/Board Member	73	17-11-30
Michael Carter BRD	Director/Board Member	86	19-06-06
Charles Theuer BRD	Director/Board Member	60	18-04-30
Jill DeSimone BRD	Director/Board Member	68	23-01-02
Robert Wills BRD	Director/Board Member	70	19-06-06
Xin Nakanishi BRD	Director/Board Member	62	18-10-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,959,645	2,686,463 ( 90.77 %)	0	90.77 %

Name	Equities	%	Valuation
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD 5.988 %	177,222	5.988 %	1 M $
Vanguard Global Advisers LLC 4.833 %	143,043	4.833 %	1 M $
Millennium Management LLC 3.483 %	103,095	3.483 %	783 522 $
BlackRock Institutional Trust Co. NA 1.327 %	39,278	1.327 %	298 513 $
James Breitmeyer 1.080 %	31,977	1.080 %	243 025 $
David Hale 1.058 %	31,304	1.058 %	237 910 $
Hale BioPharma Ventures LLC 1.003 %	29,673	1.003 %	225 515 $
Quantum Private Wealth LLC 0.9395 %	27,806	0.9395 %	211 326 $
Dimensional Fund Advisors LP (13F Subfiler) 0.8748 %	25,892	0.8748 %	196 779 $
Richmond Brothers, Inc. 0.8344 %	24,696	0.8344 %	187 690 $

Oncternal Therapeutics, Inc.

12230 El Camino Real Suite 230

92130, San Diego

http://www.oncternal.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+23.50%	47.07B
LONZA GROUP AG	+47.64%	42.06B
IQVIA HOLDINGS INC.	-5.16%	39.98B
ALNYLAM PHARMACEUTICALS, INC.	+36.37%	33.02B
CELLTRION, INC.	-7.79%	27.9B
ICON PUBLIC LIMITED COMPANY	+18.06%	27.63B
UNITED THERAPEUTICS CORPORATION	+47.29%	14.37B
MEDPACE HOLDINGS, INC.	+41.91%	13.45B
BIO-TECHNE CORPORATION	-1.02%	12.03B

Other Biotechnology & Medical Research